BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31917801)

  • 1. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    Miao R; Badger TC; Groesch K; Diaz-Sylvester PL; Wilson T; Ghareeb A; Martin JA; Cregger M; Welge M; Bushell C; Auvil L; Zhu R; Brard L; Braundmeier-Fleming A
    PLoS One; 2020; 15(1):e0227707. PubMed ID: 31917801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
    Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
    BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential tools for predicting response to chemotherapy in OC: Assessment of immune dysbiosis, participant's self-rated health and microbial dynamics.
    Badger T; Anderson E; Nelson S; Groesch K; Wilson T; Diaz-Sylvester P; Delfino K; Le N; Brard L; Braundmeier-Fleming A
    J Reprod Immunol; 2024 Jun; 163():104241. PubMed ID: 38492533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of serum human epididymis protein 4 and cancer antigen 125 in the patients with ovarian carcinoma: A protocol for systematic review and meta-analysis.
    Dai HY; Hu F; Ding Y
    Medicine (Baltimore); 2021 May; 100(21):e25981. PubMed ID: 34032711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of human epididymis 4, D-dimer, and fibrinogen compared with CA 125 alone in triaging women presenting with pelvic masses: a retrospective cohort study.
    McKendry K; Duff S; Huang Y; Redha M; Scanlon Á; Abu Saadeh F; Gleeson N; O'Leary J; Norris L; O'Toole S
    Acta Obstet Gynecol Scand; 2021 Jul; 100(7):1239-1247. PubMed ID: 33590896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases.
    Chudecka-Głaz A; Cymbaluk-Płoska A; Menkiszak J; Sompolska-Rzechuła A; Byra E; Rzepka-Górska I
    J Ovarian Res; 2014 Feb; 7():22. PubMed ID: 24528554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors.
    Xiao F; Zhang L; Yang S; Peng K; Hua T; Tang G
    J Ovarian Res; 2022 Jan; 15(1):13. PubMed ID: 35062992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
    Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
    J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
    El Bairi K; Afqir S; Amrani M
    Curr Drug Targets; 2020; 21(10):1026-1033. PubMed ID: 32334501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
    Mansha M; Gill A; Thomson PC
    Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.